Ampio Pharmaceuticals (AMPE) Competitors $0.0027 0.00 (0.00%) As of 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, PXMD, CALA, CLVR, and EFTRShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), PaxMedica (PXMD), Calithera Biosciences (CALA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma PaxMedica Calithera Biosciences Clever Leaves eFFECTOR Therapeutics Evelo Biosciences (NASDAQ:EVLO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Is EVLO or AMPE more profitable? Company Net Margins Return on Equity Return on Assets Evelo BiosciencesN/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A Which has more volatility & risk, EVLO or AMPE? Evelo Biosciences has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 4.69, indicating that its share price is 369% more volatile than the S&P 500. Does the media prefer EVLO or AMPE? In the previous week, Evelo Biosciences had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Ampio Pharmaceuticals. Evelo Biosciences' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Evelo Biosciences Neutral Ampio Pharmaceuticals Neutral Do insiders & institutionals hold more shares of EVLO or AMPE? 0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, EVLO or AMPE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvelo BiosciencesN/AN/A-$114.53MN/AN/AAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00 SummaryAmpio Pharmaceuticals beats Evelo Biosciences on 4 of the 5 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$853.50M$5.74B$21.17BDividend YieldN/A4.84%4.40%3.54%P/E Ratio0.001.1530.4129.01Price / SalesN/A26.26428.9771.28Price / CashN/A19.5625.7818.23Price / Book0.006.779.704.72Net Income-$8.63M-$4.17M$3.27B$995.89M7 Day PerformanceN/A3.84%3.94%2.56%1 Month PerformanceN/A2.35%3.81%2.81%1 Year PerformanceN/A12.14%31.26%11.07% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+3.8%$3KN/A0.0020Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpHigh Trading VolumeSTABStatera BiopharmaN/A$0.00flatN/A-66.7%$5KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002CALACalithera Biosciences0.6076 of 5 stars$0.00-80.0%N/A-98.4%$1KN/A0.0060Gap DownCLVRClever LeavesN/A$0.00+50.0%N/A-99.0%$1K$17.42M0.00560Gap UpEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.6%$1KN/A0.0010 Related Companies and Tools Related Companies Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors PaxMedica Competitors Calithera Biosciences Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access